ASSET PURCHASE AGREEMENT

+

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

1.1.4.1

any applicable domestic or foreign law including any statute, subordinate legislation or treaty, and

1.1.4.2

any applicable guideline, directive, rule, standard, requirement, policy, order, judgment, injunction, award or decree of a Governmental Authority having the force of law;

1.1.5

" Assets " means all of Oncothyreon’s right, title and interest in and to all of the assets that Oncothyreon uses to carry on the Purchased Business as of December18, 2008 (or in the six months prior to December18, 2008, has used to carry on the Purchased Business subject to ordinary course of business changes, sales, replacements, alterations, disposals, usage, breakage, and the like, during such period) including, without limiting the generality of the foregoing: (i) the Lease; (ii) the Leased Premises Assets; (iii) the Manufacturing Contracts; (iv) the Inventory Assets; and (v) the Other Assets but excluding for greater certainty the Excluded Assets;

1.1.6

" Assumed Liabilities " has the meaning set out in Section 2.7;

1.1.7

" Books and Records " means: the books, records and accounts of the Purchased Business and includes, without limitation, all material documents, data, information and correspondence (including general correspondence in writing or

+

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

1.1.17.1

reporting, licensing, permitting, investigating, remediating and cleaning up in connection with any presence or Release, or the threat of the same, of Hazardous Substances, and

1.1.17.2

the manufacture, processing, distribution, use, treatment, storage, disposal, transport, handling and the like of Hazardous Substances, including those pertaining to occupational health and safety;

1.1.18

" Excluded Assets " means those items described in Schedule O to this Agreement;

1.1.19

" Excluded Liabilities " has the meaning set out in Section 2.8;

+

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

+

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

received by the Indemnified Party, and (iii) any indirect, special or consequential damages or loss of profits;

1.1.30

" Manufacturing Contracts " means all of Oncothyreon’s right, title and interest in those contracts related to the development, manufacture, testing and release of BLP25 set forth in Schedule C to this Agreement;

1.1.31

" Material Adverse Effect " means, when used in connection with the Purchased Business, any change, event, violation, inaccuracy, circumstance or effect that is or could reasonably be expected to be materially adverse to the business, assets, liabilities, financial condition, results of operations of the Purchased Business;

1.1.32

" Notice of Claim " means a written notice from an Indemnified Party to an Indemnifying Party of any event, omission or occurrence which the Indemnified Party has determined will or could give rise to Losses which are indemnifiable under this Agreement;

1.1.33

" Other Assets " means, when used in connection with the Purchased Business, all of Oncothyreon’s right, title and interest in the assets listed in Schedule D to this Agreement;

1.1.34

" Party " means a party to this Agreement and " Parties " means all of them;

1.1.35

" Personal Information " has the meaning set forth in Section 5.3;

1.1.36

" Premises " means the premises that are the subject of the Lease;

1.1.37

" Privacy Laws " has the meaning set forth in Section 5.3;

1.1.38

" Purchase Price " has the meaning set forth in Section 2.1;

1.1.39

" Purchased Business " means, solely in relation to BLP25, all activities at present and generally during the six (6) month period preceding the Closing Date carried on by Oncothyreon on a global basis specifically related to the business of developing or optimizing manufacturing processes, developing or optimizing drug substances, drug products and drug product presentations, developing or optimizing analytical test methods, manufacturing, testing, releasing and supplying BLP25;

1.1.40

" Release " means any release or discharge of any Hazardous Substance including any discharge, spray, injection, inoculation, abandonment, deposit, spillage, leakage, seepage, pouring, emission, emptying, throwing, dumping, placing, exhausting, escape, leach, migration, dispersal, dispensing or disposal;

1.1.41

" Specifications " means, with respect to the Inventory Assets, the specifications in relation thereto set forth in Schedule P hereto; and

+

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

In this Agreement:

1.2.1

the inclusion of headings and a table of contents are for convenience of reference only and are not to be considered or taken into account in construing the provisions of this Agreement or to in any way qualify, modify or explain the effect of any such provisions;

1.2.2

unless the context otherwise requires, references to an Article, Section, Subsection, paragraph or Schedule, by number, letter or otherwise refer to the article, section, subsection, paragraph or schedule, as the case may be, bearing that designation in this Agreement;

1.2.3

words importing the singular shall include the plural and vice versa and words importing a particular gender shall include all genders;

1.2.4

wherever the words "include", "includes" or "including" are used, they shall be deemed to be followed by the words "without limitation" and the words following "include", "includes" or "including" shall not be considered to set forth an exhaustive list;

1.2.5

the words "hereof", "herein", "hereto", "hereinafter", "hereunder", "herby" and similar expressions shall be construed as referring to this Agreement in its entirety and not to any particular section or portion of it;

1.2.6

all monetary amounts are expressed in United States currency;

1.2.7

where a term is defined in this Agreement, a derivative of that term shall have a corresponding meaning unless the context otherwise requires; and

1.2.8

the term "actual knowledge of Oncothyreon" shall refer to the actual knowledge of Robert Kirkman, Ed Taylor and Gary Christianson.

+

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

+

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

2.7.1

those obligations and liabilities set forth in Schedule F; and

+

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

Except as specifically set forth in Section 3.1 and 3.4 of this Agreement:

2.10.1

EMD and Merck acknowledge and agree that all of the Assets are being sold by Oncothyreon to EMD and Merck, as the case may be, under this Agreement on an "as is where is" basis; and

2.10.2

Oncothyreon makes no representation or warranty, whether express or implied, with respect to the Assets and/or the Transferred Employees including, without limitation, any representation as to fitness for a particular purpose or merchantable quality.

3.1.1

Oncothyreon Canada has been duly incorporated and organized and is a validly subsisting corporation under the laws of Canada;

+

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

3.1.2

Biomira Management has been duly incorporated and organized and is a validly subsisting corporation under the laws of Delaware;

3.1.3

Oncothyreon Parent has been duly incorporated and organized and is a validly subsisting corporation under the laws of Delaware;

3.1.4

Oncothyreon has all requisite power and authority to enter into and perform all of its obligations under this Agreement;

3.1.5

the execution, delivery and performance by Oncothyreon of this Agreement has been duly and validly authorized by all necessary action of Oncothyreon;

3.1.6

this Agreement is a valid and binding obligation of Oncothyreon enforceable in accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization and other laws affecting creditor’s rights generally and the discretionary nature of certain remedies (including specific performance and injunctive relief);

3.1.7

the execution and delivery of this Agreement by Oncothyreon and the consummation by Oncothyreon of the transactions contemplated by this Agreement have been duly and validly authorized and will not violate, nor be in conflict with, in either case in a material adverse manner:

3.1.7.1

any of the articles, by-laws or charter documents of Oncothyreon;

3.1.7.2

any provisions of any agreement or instrument to which Oncothyreon is a party or by which it is bound; or

3.1.7.3

any law applicable to Oncothyreon or the Assets;

3.1.8

there are no liens for taxes upon the Assets, except for statutory liens for current taxes not yet due;

3.1.9

Oncothyreon Canada is a GST registrant and has a subsisting GST registration number of 106795784RT0001;

3.1.10

Oncothyreon Canada is not a non-resident of Canada within the meaning of the Income Tax Act (Canada);

3.1.11

Oncothyreon has not incurred any obligation or liability, contingent or otherwise, for brokers’ or finders’ fees in respect of the transactions contemplated by this Agreement for which EMD shall have any obligation or liability;

3.1.12

the Assets are all of the material assets used in carrying on of the Purchased Business;

3.1.13

no portion of the Purchased Business is being conducted by anyone other than Oncothyreon;

+

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

3.1.23.1

the provisions of any of its contracts; or

3.1.23.2

any Applicable Laws;

+ 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

3.1.24

the operation of the Assets is in compliance with all Applicable Laws;

3.1.25

all material consents, licenses, permits and approvals required for the operation of the Assets have been obtained and are in good standing in all material respects;

3.1.26

other than this Agreement, there is no agreement, option or other right or privilege outstanding in favour of any person for the purchase from Oncothyreon of any or all of the Assets;

3.1.27

the Books and Records have been maintained in the usual and ordinary course, consistent with past practice and all material transactions relating to the Purchased Business have been accurately recorded in such Books and Records and, other than in the ordinary course of business, such Books and Records have not been altered nor has any information been destroyed;

3.1.28

other than where the contrary would not materially and adversely impact title to, or the value of, the Assets or would not create any liability or obligation of EMD following the Closing Time:

3.1.28.1

Oncothyreon has not received any written notice of any non-compliance with any Environmental Law;

3.1.28.2

Oncothyreon has not received any order or directive which relates to environmental matters and which requires any work, repairs, construction or capital expenditure;

3.1.28.3

Oncothyreon has not received any demand or notice with respect to the breach of any Environmental Law applicable to Oncothyreon or the Purchased Business;

3.1.28.4

to the actual knowledge of Oncothyreon, there are no claims, investigations or inquiries pending or threatened against Oncothyreon based on non-compliance with any Environmental Law;

3.1.28.5

Oncothyreon has not received any claim, complaint, notice, letter of violation, inquiry or request for information involving any matter which remains unresolved as of the date hereof with respect to any alleged violation of any Environmental Law or regarding potential liability under any Environmental Law; and

3.1.28.6

there are no sites, locations or operations at which Oncothyreon is currently undertaking, or has completed, any removal, remedial or response action relating to any disposal or Release of environmental contaminants, as required by Environmental Laws;

+

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

+

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

3.2.1

EMD has been duly incorporated and organized and is a validly subsisting corporation under the laws of Ontario;

3.2.2

Merck has been duly incorporated and organized and is a validly subsisting corporation under the laws of Germany;

3.2.3

EMD has all requisite power and authority to enter into and perform all of its obligations under this Agreement;

3.2.4

Merck has all requisite power and authority to enter into and perform all of its obligations under this Agreement;

3.2.5

the execution, delivery and performance by EMD and Merck of this Agreement has been duly and validly authorized by all necessary action of EMD and Merck and this Agreement is a valid and binding obligation of EMD and Merck enforceable in accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization and other laws affecting creditor’s rights generally and the discretionary nature of certain remedies (including specific performance and injunctive relief);

+

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

3.2.6.1

any of the articles, by-laws or charter documents of EMD or Merck, as the case may be;

3.2.6.2

any provisions of any agreement or instrument to which EMD and/or Merck is a party or by which it is bound; or

3.2.6.3

any law applicable to EMD and/or Merck or the Assets;

3.2.7

EMD is a GST registrant and has a subsisting GST registration number of 12397 5260 RT; and

3.2.8

neither EMD nor Merck has incurred any obligation or liability, contingent or otherwise, for brokers’ or finders’ fees in respect of the transactions contemplated by this Agreement for which Oncothyreon shall have any obligation or liability.

3.3.1

the representations and warranties set forth in Sections 3.1.5 and 3.1.16 shall continue in full force and effect following the Closing Date; and

3.3.2

all other representations and warranties shall continue in full force and effect until the expiration of a period of one (1) year from the Closing Date.

3.4.1

Notwithstanding any other provision to the contrary in this Agreement, the sole liability of Oncothyreon in relation to the Inventory Assets (including, without limitation, the representation and warranty in Section 3.1.16 of this Agreement) shall be to refund to Merck the amount paid by Merck pursuant to this Agreement and / or the Amended and Restated Supply Agreement (2006) (less any amount paid by Oncothyreon to Baxter Pharmaceutical Solutions LLC) in respect of any Inventory Assets which, after complying with Section 3.4.2, are found not to conform with the Specifications.

3.4.2

The Parties agree, notwithstanding any provision to the contrary in this Agreement or any other agreement, that Merck shall be responsible for properly releasing the Inventory Assets and shall diligently pursue all such actions (including without limitation under the Manufacturing Contracts) that are necessary and/or desirable to permit the Inventory Assets to be released in a timely manner in accordance with the applicable Specifications. The Parties shall cooperate in such regard. If, after complying with its obligations above, Merck

+

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

4.1.1

a breach of the representations and warranties of Oncothyreon under this Agreement;

4.1.2

a breach of any covenant or agreement of Oncothyreon contained in this Agreement;

4.1.3

subject to EMD and Merck complying with their obligations under this Agreement in relation to the Transferred Employees, any liability relating to the employment in connection with the Purchased Business by Oncothyreon of any employees of Oncothyreon other than Transferred Employees who accept job offers with EMD and/or Merck; and

4.1.4

any Excluded Liabilities.

+

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

4.2.1

a breach of the representations and warranties of EMD and/or Merck under this Agreement;

4.2.2

a breach of any covenant or agreement of EMD and/or Merck contained in this Agreement; and

4.2.3

any Assumed Liabilities.

4.3.1

other than claims under Section 3.4 hereof or claims in respect of Section 3.1.5 hereof, neither EMD nor Merck shall be entitled to recover any losses, damages or costs (including without limitation Losses) from Oncothyreon as a result of the indemnities set out in Section 4.1 hereof or otherwise under this Agreement until the aggregate amount of such losses, damages or costs equals or exceeds the sum of $50,000 ;

4.3.2

the sum of $1,500,000 (plus any amounts properly owing by Oncothyreon to Merck pursuant to Section 3.4 hereof) represents the maximum aggregate liability of Oncothyreon under this Agreement and as such the maximum aggregate amount of the losses, damages and costs (including without limitation Losses) that EMD and Merck are entitled to recover from Oncothyreon as a result of the indemnities set out in Section 4.1 hereof or otherwise under this Agreement other than claims made in relation to a breach of Section 3.1.5 in which case the maximum aggregate liability of Oncothyreon under this Agreement shall be

+

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

4.3.4.1

any net tax benefit to the Indemnified Party; or

4.3.4.2

any recovery, settlement or otherwise under or pursuant to any insurance coverage, or pursuant to any claim, recovery, settlement or payment by or against another person;

4.3.5

no Party shall have the right to bring any proceedings against any other Party for a breach of any representation, warranty, covenant or agreement contained in this Agreement, except for a proceeding brought in accordance with the provisions of this Article 4; and

4.3.6

no Party shall have any liability to any other Party or any other person pursuant to this Agreement for any special, indirect or consequential damages, including but not limited to loss of profits, loss of business opportunities or loss of business investment.

4.4.1

The Indemnified Party shall notify the Indemnifying Party by a Notice of Claim which shall be given promptly after the Indemnified Party becomes aware of its own claim or that of a third party. A Notice of Claim shall specify in reasonable detail the nature and any particulars of the event, omission or occurrence giving rise to a right of indemnification hereunder. With respect to any Notice of Claim, other than a third party claim, following receipt of Notice of Claim from the Indemnified Party, the Indemnifying Party shall have thirty (30) days to make such investigation of the Claim as is considered necessary or desirable. For the

+

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

+

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

5.1.1

Except as otherwise contemplated by the Agreement or consented to in writing by EMD, from the date of this Agreement until Closing, Oncothyreon covenants and agrees with EMD as follows:

5.1.1.1

to carry on the Purchased Business in the usual and ordinary course, consistent with past practice, provided that all acts and proceedings involving a commitment in excess of $25,000 or for more than three months duration will be subject to the prior approval of EMD, which approval will not be unreasonably withheld;

5.1.1.2

to use all reasonable commercial efforts to preserve intact the Assets and the Purchased Business, organization and goodwill, to keep available the employees of the Purchased Business as a group and to maintain satisfactory relationships with suppliers and others with whom the Purchased Business has business relationships;

5.1.1.3

to use all reasonable commercial efforts to cause its current insurance policies with respect to the Purchased Business not to be cancelled or terminated or any other coverage thereunder to lapse, unless simultaneously with such terminations, cancellation or lapse, replacement policies underwritten by insurance companies of nationally recognized standing providing coverage equal to or greater than the coverage under the cancelled, terminated or lapsed policies, and where possible, for substantially similar premiums, are in full force and effect;

5.1.1.4

with their December 31, 2008 pay packages, Oncothyreon Canada shall pay to the Transferred Employees all unpaid wages, bonuses, salaries, holiday pay, vacation pay, termination pay, severance pay, change of control payments and retention payments due up to such date (with EMD to reimburse Oncothyreon Canada for such payments relating to the period from the Closing Time to December 31, 2008 as per the transition services agreement with respect thereto entered into between EMD and Oncothyreon Canada);

5.1.1.5

to promptly advise EMD in writing of the occurrence of any Material Adverse Effect in respect of the Purchased Business or of any facts that come to their attention which would cause any of Oncothyreon’s representations and warranties herein contained to be untrue in any respect;

5.1.1.6

to maintain the Books and Records in the usual and ordinary course,

+

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

5.1.1.8.1

a certificate or other instrument of Oncothyreon or of officers of Oncothyreon as EMD or EMD’s counsel may reasonably think necessary in order to establish that the obligations and covenants contained in this Agreement to have been performed or complied with by Oncothyreon at or prior to the Closing Time have been performed or complied with and that the representations and warranties of Oncothyreon herein given are true and correct at the Closing Time;

5.1.1.8.2

a favourable opinion of Oncothyreon’s counsel substantially in the form set out in Schedule L;

5.1.1.8.3

evidence of continuing insurance for any obligations or liabilities arising before the Closing Date but for which a claim has only been submitted following the Closing Date; and

5.1.1.8.4

the following documents:

a)

a certified copy of the resolutions of the directors of each of Oncothyreon Canada, Biomira Management and Oncothyreon Parent approving the execution of this Agreement and matters related thereto;

b)

a certified copy of the resolutions of the shareholders of Oncothyreon Canada and Biomira Management approving the sale of all or substantially all assets;

c)

the transition services agreement between Oncothyreon Canada and EMD;

d)

the License Agreement;

+

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

i)

the Manufacturing Contracts; and

ii)

the Lease;

f)

assignment agreements in respect of:

i)

the Manufacturing Contracts;

ii)

the Lease;

iii)

the equipment lease, dated January 26, 2006, between Dell Financial Services Canada and Biomira Inc.; and

iv)

the technology lease, dated September 20, 2007, between Compugen Finance Inc. and Biomira Inc.; and

g)

the general conveyance between Oncothyreon, EMD and Merck.

5.1.1.9

on the Closing Date, Oncothyreon shall deliver to EMD sole and exclusive physical possession of all keys, lock combinations, safe combinations, computer passwords, properties, assets, books, records, documents and other items applicable to the Assets and the Purchased Business; and

5.1.1.10

Biomira Management will have delivered to Corixa Corporation (d/b/a GlaxoSmithKline Biologicals N.A.) a Firm Forecast, pursuant to the supply agreement dated October 20, 2004, as amended, of its requirements for Licensed Adjuvant in each of the eight calendar quarters for the period beginning on April 1, 2009 and ending on March 31, 2011.

5.2.1

Except as otherwise contemplated by this Agreement or consented to in writing by Oncothyreon, from the date of this Agreement until Closing, EMD and Merck covenant and agree with Oncothyreon as follows:

5.2.1.1

on or before the Closing Date, EMD and Merck shall take all corporate action necessary to ratify the execution of this Agreement and to authorize the performance of all covenants to be performed by EMD and Merck pursuant to this Agreement;

5.2.1.2

on the Closing Date, EMD and Merck shall pay the Purchase Price to

+

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

5.2.1.3.1

the following documents:

a)

an employment agreement, in the form set out in Schedule J, entered into by each of the Key Employees;

b)

the transition services agreement between Oncothyreon Canada and EMD;

c)

assignment agreements in respect of:

i)

the Manufacturing Contracts;

ii)

the Lease;

iii)

the equipment lease, dated January 26, 2006, between Dell Financial Services Canada and Biomira Inc.; and

iv)

the technology lease, dated September 20, 2007, between Compugen Finance Inc. and Biomira Inc.; and

d)

the general conveyance between Oncothyreon, EMD and Merck..

5.2.1.4

on the Closing Date, Merck shall deliver or cause to be delivered to Oncothyreon

5.2.1.4.1

the following documents:

a)

the License Agreement; and

b)

the general conveyance between Oncothyreon, EMD and Merck.

5.3.1

EMD and Merck acknowledge and agree that EMD and Merck must comply at all times with Privacy Laws which govern the collection, use and disclosure of Personal Information disclosed to EMD and/or Merck pursuant to or in connection with this Agreement (the " Disclosed Personal Information ").

5.3.2

Neither EMD nor Merck shall use the Disclosed Personal Information for any

+

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

+

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

6.2.1

induce or endeavour to induce any person employed by Oncothyreon, other than Transferred Employees, to leave his or her employment with Oncothyreon; or

6.2.2

employ or attempt to employ or assist any person to employ any person employed by Oncothyreon, other than Transferred Employees.

+

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

(i)

the sale and purchase of the Assets contemplated hereby; or

(ii)

the right of EMD to conduct the Purchased Business;

7.2.4

non-competition agreements shall have been entered into between the Key Employees and EMD, substantially in the form set out in Schedule I;

7.2.5

employment agreements shall have been entered into between each of the Key Employees and EMD, substantially in the form set out in Schedule J;

7.2.6

Biomira Management will have entered into the License Agreement;

7.2.7

no Material Adverse Effect will have occurred in relation to the Purchased Business from the date hereof to the Closing Time; and

7.2.8

all necessary steps and proceedings will have been taken to permit the Assets to be duly and regularly transferred to and registered in the name of EMD (or as directed by EMD) including obtaining the consents to the assignments of any contracts or other commitments as set forth in the Disclosure Schedule.

+

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

7.5.1

by Oncothyreon or EMD if a material breach of any representation, warranty, covenant, obligation or other provision of this Agreement has been committed by the other party and such breach has not been waived or cured within 30 days following the date on which the non-breaching party notifies the other party of such breach;

7.5.2

by EMD if any condition in Section 7.2 has not been satisfied as of the Closing Time and EMD has not waived such condition on or before the Closing Date;

7.5.3

by Oncothyreon if any condition in Section 7.3 has not been satisfied as of the Closing Time and Oncothyreon has not waived such condition on or before the Closing Date;

7.5.4

by written agreement of Oncothyreon and EMD; or

7.5.5

by Oncothyreon or EMD if the Closing has not occurred by January 30, 2009.

+

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

Biomira Management, Inc.
2601 Fourth Avenue, Suite 500
Seattle WA 98121
United States of America
Attention: President
Facsimile: (206) 801-2101

+

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

2695 North Sheridan Way
Suite 200
Mississauga, Ontario
L5K 2N6
Attention: President
Facsimile: (905) 919-0299

8.5.3

In the case of Merck:

Merck KGaA
Frankfurter Strasse 250
D-64293 Darmstadt
Germany
Attention: Merck Serono Legal Department
Facsimile: +49-6151-72-2373

+

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

+

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

Dept

Net Book

Serial

Model

Code

Number

Description

Purch Date

Purch Price

Value

Manufacturer

Number

Number

AFE #

Location

2050

1127

3com linkswitch 1000 100b-fx d

29-May-97

5,200.00

0.00

2050

1128

3com superstack II switch 300

29-May-97

7,799.00

0.00

2050

1129

3com superstack II switch 1000

29-May-97

14,739.00

0.00

2050

1193

IBM PC server

7-Jul-98

16,000.00

0.00

23P5206

2050

1269

Proxima projector

28-Feb-00

6,008.00

0.00

00-2-010

2050

1283

Xerox N3225, HP laserjet 4050T

15-May-00

11,422.00

0.00

HPUSBB 012481

00-2-017

2050

1319

Computer (former lease)

8-Jul-01

34,571.76

0.00

01-2-004

SRVRM

2050

1324

Buyout of Lease

31-Aug-01

41,175.65

0.00

01-2-012

2050

1332

Computer Lease — reclass to

30-Nov-01

154,962.20

0.00

2050

1403

Scanner, Fujitsu

30-Sep-03

12,000.00

0.00

Fujitsu

504441

FI-4750C

03-4-019

IS

2050

1409

Hewlett-Packard Comp (BUSA)

20-Dec-04

69,166.22

0.00

Hewlett Packard

100123

2050

1417

Dell Financial Computer Lease

13-Jul-05

139,732.38

0.00

Dell/HP

2/5/1932

2050

1434

Citrix WANScalers 8500

19-Jun-07

8,550.91

5,225.49

Compugen

ORB-7500-1

NETCIR7500

2/7/1951

2050

1435

Leased HP Computer servers

28-Sep-07

163,524.70

104,474.15

Compugen

HP Servers (SAN)

2/7/1952

2050

1441

HP 4050 TN Printer

1-Aug-00

2,247.42

0.00

2050

1452

Dell Computers BuyOutEndofTerm

8-Jul-08

25,105.00

23,012.92

Dell/HP

2/8/2005

Edmonton

2050

1459

MPSM6110 IMPRNTR/STMPS/SDDL F6

30-Sep-08

5,625.12

5,468.87

100E5487

MPSM6110

2060

1440

Xerox Workcentre 7665

7-Nov-07

31,500.00

25,725.00

Xerox

VDR548760

WC 7665

8/7/1958

2060

1449

Xerox Workcentre 4150XF

26-May-08

4,299.00

3,109.12

Xerox

L99041198

4150XF

2060

1450

Walk-in Cooler

3-Jun-08

17,848.00

17,489.75

Edmonton, AB

2060

1458

Xerox Workcentre 4150S

30-Sep-08

4,299.00

4,227.35

Xerox

L99358267

WC4150S

2070

1

van

1-Jan-92

3,500.00

0.00

Dodge

VIN 2B7GB13TSHK278889

RAM150

2070

160

Biomira Sign & Plaque

15-Jun-92

8,121.50

0.00

2070

177

Biomira North Renovations

29-Jun-92

18,227.00

0.00

2070

270

Electrical & Add-on Furniture

20-Aug-92

8,370.50

0.00

2070

298

Forma Model 6097 Glassware Ste

8-Sep-92

8,933.80

0.00

Forma

51354-375

6097

B204

2070

299

Fury Glassware Dryer Model 609

8-Sep-92

9,000.00

0.00

Forma

51354-376

6097

F113

2070

403

Low Temperature Calibration Un

16-Nov-92

6,610.00

0.00

TECHNE

31728/1

DB45M

Metrology

2070

404

High Temperature Calibration U

16-Nov-92

7,400.00

0.00

TECHNE

30913/1

DB1200M

Metrology

2070

453

Vivarium Cage & Bottle Washer

28-Jan-93

36,000.00

0.00

Better Built

6855

550

VIVARIUM

2070

479

Waste Storage Building

22-Feb-93

10,263.00

0.00

2070

495

Renovati